IDXX Stock Recent News
IDXX LATEST HEADLINES
Idexx Laboratories (IDXX) concluded the recent trading session at $519.81, signifying a +0.99% move from its prior day's close.
Idexx (IDXX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The strength of the CAG Diagnostics business buoys optimism for IDEXX (IDXX).
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 29, 10:50 am – 11:30 am EST – Brian McKeon, Executive Vice President and Chief Financial Officer, and Tina Hunt, PhD, Executive Vice President, Strategy, Sector Development and Global Operations, will participate in a fireside chat at the BofA Securities Animal Health Virtual Summit. Monday, March 4, 11:00 am –.
IDEXX's (IDXX) Vello software is an intuitive solution designed specifically for practice management software that enables practitioners to interact with pet owners before and after visits.
IDEXX Laboratories, Inc. IDXX is likely to grow in the coming quarters, backed by the sustained success of CAG's recurring diagnostic products and services. The company's international business performance is gaining from its expanded global commercial capability.
A key element of IDEXX's (IDXX) customer engagement strategy is the expansion of its commercial footprint in a disciplined approach.
IDEXX Laboratories, Inc. (IDXX) Q4 2023 Earnings Call Transcript
Across testing modalities, IDEXX (IDXX) achieves strong global growth in the fourth quarter.